{"id":569749,"date":"2026-10-07T15:00:00","date_gmt":"2026-10-07T13:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/un-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario\/"},"modified":"2026-10-12T16:51:30","modified_gmt":"2026-10-12T14:51:30","slug":"un-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/un-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario\/","title":{"rendered":"\u00bfUn inhibidor de SGLT-2 y\/o un mim\u00e9tico de la incretina como tratamiento complementario?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>En la actualidad, la elecci\u00f3n del tratamiento farmacol\u00f3gico ya no se basa \u00fanicamente en el<sub>valor inicial de la HbA1c<\/sub>, sino tambi\u00e9n en los factores de riesgo o en las enfermedades concomitantes, como la insuficiencia card\u00edaca, la enfermedad renal o la obesidad. Debido a su beneficio cardiorrenal adicional, se recomienda el uso de inhibidores de SGLT-2 o mim\u00e9ticos de la incretina como tratamiento complementario a la metformina en muchos pacientes con diabetes tipo 2. Adem\u00e1s, se ha demostrado que la combinaci\u00f3n de inhibidores de SGLT-2 y mim\u00e9ticos de la incretina permite obtener efectos aditivos. El hecho de que, en el caso de estos \u00faltimos, se haya consolidado ya en la pr\u00e1ctica un agonista dual de GLP-1\/GIP supone una optimizaci\u00f3n adicional de las opciones terap\u00e9uticas.<\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fun-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>En la actualidad, la elecci\u00f3n del tratamiento farmacol\u00f3gico ya no se basa \u00fanicamente en elvalor inicial de la HbA1c, sino tambi\u00e9n en los factores de riesgo o en las enfermedades&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fun-inhibidor-de-sglt-2-y-o-un-mimetico-de-la-incretina-como-tratamiento-complementario%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Diabetes tipo 2: del enfoque glucoc\u00e9ntrico al enfoque cardiorrenal-metab\u00f3lico","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11324,11483,11352,11475,11478,11377],"tags":[102875,18647,102876,23317,12033,44103,21539,23909,20820,37124,12198,94797,11666,102874,12458,94799,73062,17397,18648,72483,77225],"powerkit_post_featured":[],"class_list":["post-569749","post","type-post","status-publish","format-standard","category-rx-es","category-cardiologia","category-el-congreso-informa","category-endocrinologia-y-diabetologia","category-estudios","category-formacion-continua","category-nefrologia","tag-agonista-del-glp-1-gip","tag-agonista-del-receptor-glp-1-es","tag-beneficio-adicional-cardiorrenal","tag-dapagliflozina","tag-diabetes-tipo-2-es-2","tag-empagliflozina","tag-enfermedad-renal","tag-factores-de-riesgo","tag-forxiga-es","tag-hba1c-es","tag-insuficiencia-cardiaca-es","tag-jardiance","tag-metformina","tag-mimetico-de-la-incretina","tag-obesidad","tag-ozempic","tag-rybelsus-es","tag-semaglutida-es","tag-sglt-2-i-es","tag-tirzepatida","tag-wegovy-es","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-21 17:08:25","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/569749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=569749"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/569749\/revisions"}],"predecessor-version":[{"id":569751,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/569749\/revisions\/569751"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=569749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=569749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=569749"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=569749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}